These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 9669358)

  • 21. [Assessment of the effectiveness of using low molecular weight heparin in the prophylaxis of venous thrombo-embolic diseases in obstetrics].
    Tomiałowicz M; Florjański J; Zimmer M; Pajak J; Kłósek A
    Ginekol Pol; 2000 Sep; 71(9):1115-9. PubMed ID: 11082986
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Low-molecular-weight heparin in deep venous thrombosis. Dosage for all weight classes].
    MMW Fortschr Med; 2003 Jun; 145(24):56. PubMed ID: 12866309
    [No Abstract]   [Full Text] [Related]  

  • 23. [Successful lysis therapy of inferior vena cava and iliofemoral venous thrombosis in heparin-induced thrombocytopenia type II].
    Fischer KG
    Dtsch Med Wochenschr; 1999 Jan; 124(1-2):32-3. PubMed ID: 9951458
    [No Abstract]   [Full Text] [Related]  

  • 24. Low molecular weight heparins: prophylaxis of venous thromboembolism in surgical patients.
    Kakkar VV
    Semin Hematol; 1997 Oct; 34(4 Suppl 4):9-19. PubMed ID: 9399405
    [No Abstract]   [Full Text] [Related]  

  • 25. [Clinical experiences with Danaparoid sodium. Measures to be taken in heparin-induced thrombocytopenia].
    Anaesthesist; 1998 Nov; 47(11 Suppl Massnahmen):1-4. PubMed ID: 9884734
    [No Abstract]   [Full Text] [Related]  

  • 26. [Current status of anticoagulants].
    Oger E; Mottier D
    Presse Med; 2000 May 27-Jun 3; 29(19):1079-82. PubMed ID: 10874921
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Deep venous thrombosis--treatment].
    Fries R; Böhm M
    Dtsch Med Wochenschr; 2003 May; 128(18):999-1002. PubMed ID: 12721879
    [No Abstract]   [Full Text] [Related]  

  • 28. Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004.
    Magnani HN; Gallus A
    Thromb Haemost; 2006 Jun; 95(6):967-81. PubMed ID: 16732376
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Danaparoid for cardiopulmonary bypass in patients with previous heparin-induced thrombocytopenia.
    Gillis S; Merin G; Zahger D; Deeb M; Drenger B; Hyam E; Eldor A
    Br J Haematol; 1997 Sep; 98(3):657-9. PubMed ID: 9332322
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Conventional or low molecular weight heparin in the treatment of venous thromboembolic disease?].
    Ruiz Manzano J; Monreal M
    Med Clin (Barc); 1998 Nov; 111(18):697-9. PubMed ID: 9887434
    [No Abstract]   [Full Text] [Related]  

  • 31. [Thrombosis, low-molecular-weight heparin-induced thrombocytopenia and labor].
    Lemesle FG; Mebroukine L; Ermacora P; Lhuillier P; Marfaing A; Wolf M
    Presse Med; 1998 Jan; 27(1):19. PubMed ID: 9767759
    [No Abstract]   [Full Text] [Related]  

  • 32. Fatal danaparoid-sodium induced thrombocytopenia and arterial thromboses.
    Tardy B; Tardy-Poncet B; Viallon A; Piot M; Mazet E
    Thromb Haemost; 1998 Sep; 80(3):530. PubMed ID: 9759647
    [No Abstract]   [Full Text] [Related]  

  • 33. Danaparoid in the prevention of thromboembolic complications.
    Skoutakis VA
    Ann Pharmacother; 1997; 31(7-8):876-87. PubMed ID: 9220051
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Empiric use of anticoagulant and fibrinolytic agents in surgical therapy.
    Laufman H
    Am Surg; 1974 Jan; 40(1):15-21. PubMed ID: 4808618
    [No Abstract]   [Full Text] [Related]  

  • 35. Heparin-induced thrombocytopenia in the cardiovascular patient: diagnostic and treatment guidelines.
    Gurbuz AT; Elliott WG; Zia AA
    Eur J Cardiothorac Surg; 2005 Jan; 27(1):138-49. PubMed ID: 15621486
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Skin necrosis induced by heparin: apropos of 2 cases].
    Andolfatto S; Latger-Cannard V; Maistre ED; Briquel ME; André E; Montange F; Reichert S; Lecompte T
    Ann Biol Clin (Paris); 2001; 59(5):651-4. PubMed ID: 11602401
    [No Abstract]   [Full Text] [Related]  

  • 37. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: the clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban.
    Laposata M; Green D; Van Cott EM; Barrowcliffe TW; Goodnight SH; Sosolik RC
    Arch Pathol Lab Med; 1998 Sep; 122(9):799-807. PubMed ID: 9740137
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heparin-induced thrombocytopenia and antithrombotic therapy.
    Boon DM; Michiels JJ; Stibbe J; van Vliet HH; Kappers-Klunne MC
    Lancet; 1994 Nov; 344(8932):1296. PubMed ID: 7526097
    [No Abstract]   [Full Text] [Related]  

  • 39. Management of venous thromboembolism: optimization by clinical trials.
    Turpie AG
    Haemostasis; 1996 Oct; 26 Suppl 4():220-6. PubMed ID: 8979127
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The prevention of thromboembolic disease in medical patients: heparin-calcium or low-molecular-weight heparin?].
    de los Santos-Sastre S
    An Med Interna; 1993 Sep; 10(9):465-6. PubMed ID: 8218806
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.